Content
June 2022, Volume 40, Issue 6
- 623-631 Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer
by Woojung Lee & William B. Wong & Stacey Kowal & Louis P. Garrison & David L. Veenstra & Meng Li - 633-645 Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups
by Ellen Rafferty & Mike Paulden & Sarah A. Buchan & Joan L. Robinson & Julie A. Bettinger & Manoj Kumar & Lawrence W. Svenson & Shannon E. MacDonald
May 2022, Volume 40, Issue 5
- 479-488 Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults
by Donna Rowen & Clara Mukuria & Philip A. Powell & Allan Wailoo - 489-495 Assessments of the Value of New Interventions Should Include Health Equity Impact
by Jeroen P. Jansen & Thomas A. Trikalinos & Kathryn A. Phillips - 497-507 Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches
by Elamin H. Elbasha - 509-518 Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Willem Witlox & Robert Wolff & Annette Chalker & Mickael Hiligsmann & Ben Wijnen & Charlotte Ahmadu & Steve Ryder & Nigel Armstrong & Steven Duffy & Isabel Syndikus & Jos Kleijnen & Manuela A. Joore - 519-558 Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
by Min Huang & Amin Haiderali & Grace E. Fox & Andrew Frederickson & Javier Cortes & Peter A. Fasching & Joyce O’Shaughnessy - 559-574 The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
by K. Ray Chaudhuri & A. Simon Pickard & Ali Alobaidi & Yash J. Jalundhwala & Prasanna L. Kandukuri & Yanjun Bao & Julia Sus & Glynn Jones & Christian Ridley & Julia Oddsdottir & Seyavash Najle-Rahim & Matthew Madin-Warburton & Weiwei Xu & Anette Schrag - 575-575 Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Willem Witlox & Robert Wolff & Annette Chalker & Mickael Hiligsmann & Ben Wijnen & Charlotte Ahmadu & Steve Ryder & Nigel Armstrong & Steven Duffy & Isabel Syndikus & Jos Kleijnen & Manuela A. Joore
April 2022, Volume 40, Issue 4
- 359-366 Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions
by Olena Mandrik & Chloe Thomas & Sophie Whyte & James Chilcott - 367-378 Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice
by Manuel Gomes & Elizabeth Murray & James Raftery - 379-431 Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
by Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & Cate Bailey & Jonathan Craig & Kim Dalziel & Alison Hayes & Brendan Mulhern & Germaine Wong & Julie Ratcliffe & Stavros Petrou - 433-447 The EQ-5D-5L Valuation Study in Egypt
by Sahar Al Shabasy & Maggie Abbassi & Aureliano Finch & Bram Roudijk & Darrin Baines & Samar Farid - 449-460 Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia
by Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi - 461-476 Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine
by Zoë Pieters & Benson Ogunjimi & Philippe Beutels & Joke Bilcke - 477-478 Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
by Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & Cate Bailey & Jonathan Craig & Kim Dalziel & Alison Hayes & Brendan Mulhern & Germaine Wong & Julie Ratcliffe & Stavros Petrou
March 2022, Volume 40, Issue 3
- 241-248 Four Aspects Affecting Health Economic Decision Models and Their Validation
by Talitha Feenstra & Isaac Corro-Ramos & Dominique Hamerlijnck & George Voorn & Salah Ghabri - 249-256 Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time
by Gemma E. Shields & Becky Pennington & Ash Bullement & Stuart Wright & Jamie Elvidge - 257-268 Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models
by Min Huang & Scott Ramsey & Weiguang Xue & Jipan Xie & James Pellissier & Andrew Briggs - 269-295 Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations
by Sónia Romano & Débora Figueira & Inês Teixeira & Julian Perelman - 297-307 A Comparison of PROPr and EQ-5D-5L Value Sets
by Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin - 309-321 Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol
by Fan Yang & Kenneth R. Katumba & Bram Roudijk & Zhihao Yang & Paul Revill & Susan Griffin & Perez N. Ochanda & Mohammed Lamorde & Giulia Greco & Janet Seeley & Mark Sculpher - 323-339 Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
by Timothy Spelman & William L. Herring & Yuanhui Zhang & Michael Tempest & Isobel Pearson & Ulrich Freudensprung & Carlos Acosta & Thibaut Dort & Robert Hyde & Eva Havrdova & Dana Horakova & Maria Trojano & Giovanna Luca & Alessandra Lugaresi & Guillermo Izquierdo & Pierre Grammond & Pierre Duquette & Raed Alroughani & Eugenio Pucci & Franco Granella & Jeannette Lechner-Scott & Patrizia Sola & Diana Ferraro & Francois Grand’Maison & Murat Terzi & Csilla Rozsa & Cavit Boz & Raymond Hupperts & Vincent Pesch & Celia Oreja-Guevara & Anneke Walt & Vilija G. Jokubaitis & Tomas Kalincik & Helmut Butzkueven - 341-354 Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment
by Gabin F. Morillon & Thomas G. Poder - 355-355 Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies
by T. Joseph Mattingly & R. Brett McQueen & Pei-Jung Lin - 357-357 Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment
by Gabin F. Morillon & Thomas G. Poder
February 2022, Volume 40, Issue 2
- 141-147 Future Offspring Costs in Economic Evaluation
by Evelyn Verbeke & Jeroen Luyten - 149-156 Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency
by Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies - 157-182 How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents
by Cate Bailey & Kim Dalziel & Paula Cronin & Nancy Devlin & Rosalie Viney - 183-201 Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review
by Thitima Kongnakorn & Grammati Sarri & Andreas Freitag & Kinga Marczell & Paulina Kazmierska & Elizabeth Masters & Vivek Pawar & Xinke Zhang - 203-214 The Utility of a Rapid Review Evaluation Process to a National HTA Agency
by Áine Varley & Lesley Tilson & Emer Fogarty & Laura McCullagh & Michael Barry - 215-223 The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions
by Yan Meng & Philip M. Clarke & Ilias Goranitis - 225-232 Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
by James D. Chambers & Nikoletta M. Margaretos & Daniel E. Enright & Rosa Wang & Xin Ye - 233-239 The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS
by Megan Perry-Duxbury & James Lomas & Miqdad Asaria & Pieter Baal
December 2022, Volume 40, Issue 2
- 123-127 EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions
by Nancy Devlin & Bram Roudijk & Rosalie Viney & Elly Stolk - 129-137 Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L
by David J. Mott & Nancy J. Devlin & Simone Kreimeier & Richard Norman & Koonal K. Shah & Oliver Rivero-Arias - 139-146 Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L
by Jonathan L. Nazari & A. Simon Pickard & Ning Yan Gu - 147-155 Estimating an EQ-5D-Y-3L Value Set for China
by Zhihao Yang & Jie Jiang & Pei Wang & Xuejing Jin & Jing Wu & Yu Fang & Da Feng & Xiaoyu Xi & Shunping Li & Mingxia Jing & Bin Zheng & Weidong Huang & Nan Luo - 157-167 Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values
by Titi Sahidah Fitriana & Bram Roudijk & Fredrick Dermawan Purba & Jan J. V. Busschbach & Elly Stolk - 169-180 An EQ-5D-Y-3L Value Set for Belgium
by Sarah Dewilde & Bram Roudijk & Nafthali H. Tollenaar & Juan M. Ramos-Goñi - 181-192 In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives
by Stefan A. Lipman & Brigitte A. B. Essers & Aureliano P. Finch & Ayesha Sajjad & Peep F. M. Stalmeier & Bram Roudijk - 193-203 A Value Set for the EQ-5D-Y-3L in the Netherlands
by Bram Roudijk & Ayesha Sajjad & Brigitte Essers & Stefan Lipman & Peep Stalmeier & Aureliano Paolo Finch - 205-215 Value Set for the EQ-5D-Y-3L in Hungary
by Fanni Rencz & Gábor Ruzsa & Alex Bató & Zhihao Yang & Aureliano Paolo Finch & Valentin Brodszky - 217-229 EQ-5D-Y Value Set for Germany
by Simone Kreimeier & David Mott & Kristina Ludwig & Wolfgang Greiner - 231-231 Correction to: EQ-5D-Y Value Set for Germany
by Simone Kreimeier & David Mott & Kristina Ludwig & Wolfgang Greiner
January 2022, Volume 40, Issue 1
- 5-6 CHEERS to 30 Years of PharmacoEconomics
by Richard Milne & Christopher Carswell - 7-11 In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era
by Werner Brouwer & Samare Huls & Ayesha Sajjad & Tim Kanters & Leona Hakkaart-van Roijen & Job Exel - 13-29 The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
by Natalie Bohm & Sarah Bermingham & Frank Grimsey Jones & Daniela C. Gonçalves-Bradley & Alex Diamantopoulos & Jessica R. Burton & Hamish Laing - 31-43 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates
by Laura C. Edney & James Lomas & Jonathan Karnon & Laura Vallejo-Torres & Niek Stadhouders & Jonathan Siverskog & Mike Paulden & Ijeoma P. Edoka & Jessica Ochalek - 45-64 Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review
by Thomas Ward & Ruben E. Mujica-Mota & Anne E. Spencer & Antonieta Medina-Lara - 65-76 A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom
by Maria Veronica Dorgali & Alberto Longo & Caroline Vass & Gemma Shields & Roger Harrison & Riccardo Scarpa & Marco Boeri - 77-90 Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic
by Samare P. I. Huls & Ayesha Sajjad & Tim A. Kanters & Leona Hakkaart-van Roijen & Werner B. F. Brouwer & Job Exel - 91-108 The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis
by Laurenske A. Visser & Marc Folcher & Claudia Delgado Simao & Biotza Gutierrez Arechederra & Encarna Escudero & Carin A. Uyl-de Groot & William Ken Redekop - 109-120 Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations
by Daniel Gallacher & Peter Kimani & Nigel Stallard - 121-131 An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
by Marjanne A. Piena & Natalie Houwing & Carla W. Kraan & Xiaofeng Wang & Heidi Waters & Ruth A. Duffy & Suresh Mallikaarjun & Craig Bennison - 133-135 Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery
by Kevin M. Trentino & Hamish Mace & Axel Hofmann - 137-138 Authors’ Response to “Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery”
by Bert Avau & Hans Van Remoortel & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 139-139 Correction to: A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population
by Emily McDool & Clara Mukuria & John Brazier
April 2022, Volume 40, Issue 1
- 3-5 Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
by Chris Skedgel - 7-10 Importance of Patient Involvement in the Value Assessment Process: On the Way Towards Personalised Treatments
by Nicole Gusset - 11-38 Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management
by Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland - 39-67 Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers
by C. Simone Sutherland & Pollyanna Hudson & Stephen Mitchell & Noman Paracha - 69-89 Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
by Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland - 91-102 Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
by Siu Hing Lo & Ksenija Gorni & C. Simone Sutherland & Yasmina Martí & Andrew Lloyd & Noman Paracha - 103-115 Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries
by Siu Hing Lo & Claire Lawrence & Yasmina Martí & Andreia Café & Andrew J. Lloyd - 117-117 Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
by Chris Skedgel - 119-119 Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
by Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland
December 2021, Volume 39, Issue 12
- 1355-1363 Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting
by Simon Pol & Paula Rojas Garcia & Fernando Antoñanzas Villar & Maarten J. Postma & Antoinette D. I. Asselt - 1365-1372 Why the Gap in Evaluating the Social Constructs and the Value of Medicines?
by Jacquelyn McRae & Eberechukwu Onukwugha - 1373-1381 A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper
by Mikyung Kelly Seo & Mark Strong - 1383-1395 Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis
by Lidia Engel & Stirling Bryan & David G. T. Whitehurst - 1397-1410 Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Ben Wijnen & Rob Riemsma & Debra Fayter & Nigel Armstrong & Charlotte Ahmadu & Lloyd Brandts & Kate Misso & John R. Kirwan & Jos Kleijnen & Manuela A. Joore - 1411-1427 Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review
by Simon van der Pol & Paula Rojas Garcia & Maarten J. Postma & Fernando Antoñanzas Villar & Antoinette D. I. Asselt - 1429-1442 Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
by Martijn J. H. G. Simons & Valesca P. Retèl & Bram L. T. Ramaekers & Rogier Butter & Joanne M. Mankor & Marthe S. Paats & Joachim G. J. V. Aerts & Zakile A. Mfumbilwa & Paul Roepman & Veerle M. H. Coupé & Carin A. Uyl-de Groot & Wim H. van Harten & Manuela A. Joore - 1443-1454 What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK
by Liz Morrell & James Buchanan & Sian Rees & Richard W. Barker & Sarah Wordsworth - 1455-1463 Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop
by Jamie Elvidge & Dalia Dawoud
November 2021, Volume 39, Issue 11
- 1201-1208 Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic
by Yumi Asukai & Andrew Briggs & Louis P. Garrison & Benjamin P. Geisler & Peter J. Neumann & Daniel A. Ollendorf - 1209-1223 The Challenges of Measuring Informal Care Time: A Review of the Literature
by Sean Urwin & Yiu-Shing Lau & Gunn Grande & Matt Sutton - 1225-1241 The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature
by Boshen Jiao & Anirban Basu & Joshua Roth & M. Bender & Ilsa Rovira & Traci Clemons & Dalyna Quach & Scott Ramsey & Beth Devine - 1243-1269 How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment
by Michael Schlander & Karla Hernandez-Villafuerte & Chih-Yuan Cheng & Jorge Mestre-Ferrandiz & Michael Baumann - 1271-1297 A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome
by I-Wen Pan & Daniel M. Halperin & Bumyang Kim & James C. Yao & Ya-Chen Tina Shih - 1299-1308 EQ-5D-Y Population Norms for Japanese Children and Adolescents
by Takeru Shiroiwa & Takashi Fukuda - 1309-1325 Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial
by Michael Dolph & Gabriel Tremblay & Hoyee Leong - 1327-1341 Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment
by Bassem Asker & Raghad Jawad & Rabah Asreah & Haydar Jamal & Ahmed Jassem & Muslim Abdelkareem Inaya & Hiwa Abou Baker & Sam Kozma & Eid Mansour & Bryony McNamara & Ryan Miller & Oliver Darlington & Phil McEwan & Daniel M. Sugrue & Haidar Jarallah - 1343-1354 Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
by Adnan Alsumali & Laurence M Djatche & Andrew Briggs & Rongzhe Liu & Ibrahim Diakite & Dipen Patel & Yufei Wang & Dominik Lautsch
October 2021, Volume 39, Issue 10
- 1101-1107 Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies
by T. Joseph Mattingly & R. Brett McQueen & Pei-Jung Lin - 1109-1121 A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement
by Jihyung Hong & Eun-Young Bae - 1123-1139 Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis
by Bert Avau & Hans Van Remoortel & Jorien Laermans & Geertruida Bekkering & Dean Fergusson & Jørgen Georgsen & Paola Maria Manzini & Yves Ozier & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 1141-1149 Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease: A Swedish Register-Based Study in 1823 Observations
by Jenny M. Norlin & Klas Kellerborg & Per Odin - 1151-1162 Valuing SF-6Dv2 in Australia Using an International Protocol
by Brendan Mulhern & Richard Norman & John Brazier - 1163-1183 Lifetime Costs for Treated Follicular Lymphoma Patients in the US
by Caitlin Eichten & Qiufei Ma & Thomas E. Delea & May Hagiwara & Roberto Ramos & Şerban R. Iorga & Jie Zhang & Richard T. Maziarz - 1185-1196 State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
by Sabine E. Grimm & Xavier Pouwels & Bram L. T. Ramaekers & Ben Wijnen & Thomas Otten & Janneke Grutters & Manuela A. Joore - 1197-1198 Deterministic Sensitivity Analysis Under Ignorance
by Afschin Gandjour - 1199-1199 Comment on “Deterministic Sensitivity Analysis Under Ignorance”
by Rick A. Vreman & Joost W Geenen & Saskia Knies & Aukje K. Mantel-Teeuwisse & Hubert G. M. Leufkens & Wim G. Goettsch
September 2021, Volume 39, Issue 9
- 973-982 Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia
by Anna Reyes-Travé & Laura Guarga-Solé & Marta Roig-Izquierdo & Enrique Alonso-Pérez & Ana Clopés-Estela & Joaquín Delgadillo-Duarte - 983-993 Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework
by Luca M. M. Janssen & Ruben M. W. A. Drost & Aggie T. G. Paulus & Kirsty Garfield & William Hollingworth & Sian Noble & Joanna C. Thorn & Irina Pokhilenko & Silvia M. A. A. Evers - 995-1019 Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review
by Joseph Khoa Ho & Kennedy Borle & Nick Dragojlovic & Manrubby Dhillon & Vanessa Kitchin & Nicola Kopac & Colin Ross & Larry D. Lynd - 1021-1044 Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
by Karen M. Facey & Jaime Espin & Emma Kent & Angèl Link & Elena Nicod & Aisling O’Leary & Entela Xoxi & Inneke Vijver & Anna Zaremba & Tatyana Benisheva & Andrius Vagoras & Sheela Upadhyaya - 1045-1058 Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective
by Daniel Stellato & Marroon E. Thabane & Jinhee Park & David Chandiwana & Thomas E. Delea - 1059-1073 A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
by Erin Kirwin & Ellen Rafferty & Kate Harback & Jeff Round & Christopher McCabe - 1075-1084 Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)
by Michael J. Zoratti & Kelvin K. W. Chan & Don Husereau & Murray Krahn & Mitchell Levine & Lehana Thabane & Feng Xie - 1085-1098 Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment
by Aureliano Paolo Finch & Eva Gamper & Richard Norman & Rosalie Viney & Bernhard Holzner & Madeleine King & Georg Kemmler - 1099-1099 Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
by Becky Pennington & Abualbishr Alshreef & Laura Flight & Andrew Metry & Edith Poku & Philip Hykin & Sobha Sivaprasad & A. Toby Prevost & Joana C. Vasconcelos & Caroline Murphy & Joanna Kelly & Yit Yang & Andrew Lotery & Michael Williams & John Brazier
August 2021, Volume 39, Issue 8
- 869-878 Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals
by Tushar Srivastava & Nicholas R. Latimer & Paul Tappenden - 879-887 Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies
by Ana Duarte & Simon Walker & Andrew Metry & Ruth Wong & Jasmina Panovska-Griffiths & Mark Sculpher - 889-900 Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector
by Irina Pokhilenko & Luca M. M. Janssen & Silvia M. A. A. Evers & Ruben M. W. A. Drost & Lena Schnitzler & Aggie T. G. Paulus - 901-912 Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries
by Kate Williams & Daniel Aggio & Peter Chen & Katerina Anokhina & Andrew J. Lloyd & Yan Wang - 913-927 Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
by Becky Pennington & Abualbishr Alshreef & Laura Flight & Andrew Metry & Edith Poku & Philip Hykin & Sobha Sivaprasad & A. Toby Prevost & Joana C. Vasconcelos & Caroline Murphy & Joanna Kelly & Yit Yang & Andrew Lotery & Michael Williams & John Brazier - 929-940 A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population
by Emily McDool & Clara Mukuria & John Brazier - 941-952 The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden
by Fredrik O. L. Nilsson & Sandra T. Asanin & Elizabeth T. Masters & Laura Iadeluca & Chrissy Almond & Miranda Cooper & Sarah Smith - 953-964 Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer
by Yat Hang To & Koen Degeling & Suzanne Kosmider & Rachel Wong & Margaret Lee & Catherine Dunn & Grace Gard & Azim Jalali & Vanessa Wong & Maarten IJzerman & Peter Gibbs & Jeanne Tie - 965-967 Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening”
by James F. O’Mahony - 969-970 Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening
by Edna Keeney & Howard Thom & Emma Turner & Richard M. Martin & Sabina Sanghera - 971-971 Retraction Note to: The EQ-5D-5L Valuation Study in Egypt
by Sahar A. Shabasy & Maggie M. Abbassi & Aureliano Paolo Finch & Darrin Baines & Samar F. Farid
July 2021, Volume 39, Issue 7
- 741-756 Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients
by Peter Ghijben & Dennis Petrie & Silva Zavarsek & Gang Chen & Emily Lancsar - 757-770 Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies
by Huajie Jin & Stewart Robinson & Wenru Shang & Evanthia Achilla & David Aceituno & Sarah Byford - 771-788 Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine
by Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & László Szilberhorn & Tamás Zelei & Balázs Nagy & Rositsa Koleva-Kolarova & Apostolos Tsiachristas & Sarah Wordsworth & Maureen Rutten-van Mölken - 789-807 Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review
by Jalal Dahham & Rana Rizk & Ingrid Kremer & Silvia M. A. A. Evers & Mickaël Hiligsmann - 809-822 What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study
by Jakob Manthey & Syed Ahmed Hassan & Sinclair Carr & Carolin Kilian & Sören Kuitunen-Paul & Jürgen Rehm - 823-833 Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest
by Stephanie Harvard & Gregory R. Werker - 835-851 Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group
by Chantelle Murley & Petter Tinghög & Kristina Alexanderson & Jan Hillert & Emilie Friberg & Korinna Karampampa - 853-867 Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective
by Daniel Stellato & Marroon E. Thabane & David Chandiwana & Jinhee Park & Thomas E. Delea
June 2021, Volume 39, Issue 6
- 617-617 Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders
by Paul E. Greenberg & Tammy Sisitsky - 619-625 The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers
by David Proudman & Paul Greenberg & Dave Nellesen - 627-630 Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures
by Ron D. Hays & Peter M. Fayers - 631-638 Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States
by Richard Z. Xie & Erica deFur Malik & Mark T. Linthicum & Jennifer L. Bright - 639-651 Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US
by Drishti Shah & Lindsay Allen & Wanhong Zheng & Suresh S. Madhavan & Wenhui Wei & Traci J. LeMasters & Usha Sambamoorthi - 653-665 The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
by Paul E. Greenberg & Andree-Anne Fournier & Tammy Sisitsky & Mark Simes & Richard Berman & Sarah H. Koenigsberg & Ronald C. Kessler - 667-680 The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)
by Hannah König & Alexander Rommel & Julia Thom & Christian Schmidt & Hans-Helmut König & Christian Brettschneider & Alexander Konnopka - 681-690 Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors
by Jackie Yim & Joanne Shaw & Rosalie Viney & Sheena Arora & Nicole Ezendam & Alison Pearce - 691-706 The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder
by Alix Arnaud & Ellison Suthoff & Rita M. Tavares & Xuan Zhang & Aditi J. Ravindranath - 707-720 Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
by Maryia Zhdanava & Jennifer Voelker & Dominic Pilon & Tom Cornwall & Laura Morrison & Maude Vermette-Laforme & Patrick Lefebvre & Abigail I. Nash & Kruti Joshi & Cheryl Neslusan - 721-730 Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare
by Kaying Kan & Joran Lokkerbol & Frederike Jörg & Ellen Visser & Robert A. Schoevers & Talitha L. Feenstra - 731-739 Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers
by Emily J. Callander & Jenny Gamble & Debra K. Creedy
May 2021, Volume 39, Issue 5
- 481-483 Hispa-NICE: A Pipe Dream or a Realistic and Necessary Initiative?
by Fernando Antoñanzas - 485-502 Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review
by Alfredo Palacios & Carlos Rojas-Roque & Lucas González & Ariel Bardach & Agustín Ciapponi & Claudia Peckaitis & Andres Pichon-Riviere & Federico Augustovski - 503-519 Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis
by Joseph Carrello & Alison Hayes & Anagha Killedar & Amy Huben & Louise A. Baur & Stavros Petrou & Thomas Lung - 521-535 Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension
by Jing Wu & Shitong Xie & Xiaoning He & Gang Chen & Gengliang Bai & Da Feng & Ming Hu & Jie Jiang & Xiaohui Wang & Hongyan Wu & Qunhong Wu & John E. Brazier - 537-548 Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
by Yong-Jin Kim & Mark Oremus & Helen H. Chen & Thomas McFarlane & Danielle Fearon & Susan Horton - 549-561 RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt
by Sahar A. Al Shabasy & Maggie M. Abbassi & Aureliano Paolo Finch & Darrin Baines & Samar F. Farid - 563-577 Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
by Nadine Schur & Kapil Gudala & Umakanth Vudumula & Sreelatha Vadapalle & Arjun Bhadhuri & Alain Casanova & Nicholas Adlard & Matthias Schwenkglenks - 579-587 Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness
by Manuel Neves & Fernanda Trigo & Bergantim Rui & Cristina João & Paulo Lúcio & Neves Mariana & João Mendes & Hugo Pedrosa & Catarina Geraldes - 589-600 Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening
by Edna Keeney & Howard Thom & Emma Turner & Richard M. Martin & Sabina Sanghera - 601-615 Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study
by Christopher Kruse & Sabrina Kretschmer & Anna Lipinski & Malte Verheyen & David Mengel & Monika Balzer-Geldsetzer & Stefan Lorenzl & Carmen Richinger & Christian Schmotz & Lars Tönges & Dirk Woitalla & Stephan Klebe & Anette Schrag & Richard Dodel
April 2021, Volume 39, Issue 4
- 379-382 Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment
by R. Brett McQueen & Julia F. Slejko - 383-397 Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
by Simone A. Huygens & Matthijs M. Versteegh & Stefan Vegter & L. Jan Schouten & Tim A. Kanters - 399-420 Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review
by Anindit Chhibber & Alexandre Hikiji Watanabe & Chayutthaphong Chaisai & Sajesh K. Veettil & Nathorn Chaiyakunapruk - 421-432 The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States
by Anita J. Brogan & Sandra E. Talbird & Ashley E. Davis & Elizabeth M. La & Princy N. Kumar - 433-446 Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success
by Björn Schwander & Mark Nuijten & Silvia Evers & Mickaël Hiligsmann - 447-461 Macrovascular Risk Equations Based on the CANVAS Program
by Michael Willis & Christian Asseburg & April Slee & Andreas Nilsson & Cheryl Neslusan - 463-471 EQ-5D-Y Value Set for Slovenia
by Valentina Prevolnik Rupel & Marko Ogorevc - 473-475 Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
by Kelly Hollenack & Jade Marshall - 477-478 Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
by Edward E. Neuberger & Josh J. Carlson & David L. Veenstra - 479-480 The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases
by Jesse Elliott & George A. Wells & Doug Coyle
March 2021, Volume 39, Issue 3
- 271-273 Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden
by Zanfina Ademi & Ilana N. Ackerman & Ella Zomer & Danny Liew - 275-285 Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment
by Seamus Kent & Edward Burn & Dalia Dawoud & Pall Jonsson & Jens Torup Østby & Nigel Hughes & Peter Rijnbeek & Jacoline C. Bouvy - 287-315 Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data
by Marina Treskova & Francisco Pozo-Martin & Stefan Scholz & Viktoria Schönfeld & Ole Wichmann & Thomas Harder - 317-330 Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
by Elizabeth Wehler & Dominik Lautsch & Stacey Kowal & Glenn Davies & Andrew Briggs & Qianyi Li & Swapnil Rajpathak & Adnan Alsumali - 331-343 Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)
by Marwân-al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo & Charles Kouanfack & Eric Delaporte & Sylvie Boyer - 345-356 What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma
by Sven L. Klijn & Elisabeth Fenwick & Sonja Kroep & Kasper Johannesen & Bill Malcolm & Murat Kurt & Christopher Kiff & John Borrill - 357-372 Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
by Ronan Mahon & Andrea Lang & Pamela Vo & Jasper Huels & Philip Cooney & Andriy Danyliv & Umakanth Vudumula & Sreelatha Vadapalle & Farooq Maniyar & Peter J. Goadsby - 373-377 Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
by Adam J. N. Raymakers & Kristina M. Jenei & Dean A. Regier & Michael M. Burgess & Stuart J. Peacock
February 2021, Volume 39, Issue 2
- 139-146 NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests
by James F. O’Mahony & Mike Paulden & Chris McCabe - 147-160 Modifying NICE’s Approach to Equity Weighting
by Mike Paulden & Christopher McCabe - 161-169 Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve
by Pedram Sendi - 171-180 Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Willem J. A. Witlox & Sabine E. Grimm & Rob Riemsma & Nigel Armstrong & Steve Ryder & Steven Duffy & Vanesa Huertas Carrera & Pawel Posadzki & Gillian Worthy & Xavier G. L. V. Pouwels & Bram L. T. Ramaekers & Jos Kleijnen & Manuela A. Joore & Antoinette D. I. Asselt - 181-209 An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
by Nannan Li & Dennis Cornelissen & Stuart Silverman & Daniel Pinto & Lei Si & Ingrid Kremer & Sandrine Bours & Robin de Bot & Annelies Boonen & Silvia Evers & Joop van den Bergh & Jean-Yves Reginster & Mickaël Hiligsmann - 211-229 Health State Utilities of Patients with Heart Failure: A Systematic Literature Review
by Gian Luca Di Tanna & Michael Urbich & Heidi S. Wirtz & Barbara Potrata & Marieke Heisen & Craig Bennison & John Brazier & Gary Globe - 231-241 The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer
by Katrine Wallace & Kelly Adamski & Ashwini Pai & Darya Rose & Anita Chawla - 243-256 Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
by Luis Hernandez & Malinda O’Donnell & Maarten Postma - 257-269 Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs
by Baudouin Standaert & Christophe Sauboin & Quentin J. Leclerc & Mark P. Connolly
January 2021, Volume 39, Issue 1
- 1-17 The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
by Rick A. Vreman & Joost W. Geenen & Saskia Knies & Aukje K. Mantel-Teeuwisse & Hubert G. M. Leufkens & Wim G. Goettsch - 19-24 Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier
by Christopher McCabe & Giovanni Tramonti & Andrew Sutton & Peter Hall & Mike Paulden - 25-61 Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions
by Ruth A. Lewis & Dyfrig Hughes & Alex J. Sutton & Clare Wilkinson - 63-80 Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review
by Thomas Lung & Lei Si & Richard Hooper & Gian Luca Di Tanna - 81-97 Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review
by Akira Yuasa & Naohiro Yonemoto & Michael LoPresti & Shunya Ikeda - 99-108 The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best–Worst Scaling Experiment
by Irina Pokhilenko & Luca M. M. Janssen & Mickael Hiligsmann & Silvia M. A. A. Evers & Ruben M. W. A. Drost & Aggie T. G. Paulus & Leonarda G. M. Bremmers - 109-119 Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions
by Linda Yamoah & Nick Dragojlovic & Alesha Smith & Larry D. Lynd & Carlo A. Marra - 121-131 Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
by Carla Mamolo & Verna Welch & Roland B. Walter & Joseph C. Cappelleri & James Brockbank & Matthew Cawson & Chris Knight & Michele Wilson - 133-135 Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”
by Bram L. T. Ramaekers & Ben Wijnen & Nigel Armstrong & Svenja Petersohn & Talitha Feenstra & Junfeng Wang & Manuela A. Joore - 137-138 Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”
by Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos
December 2020, Volume 38, Issue 12
- 1283-1288 The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?
by David G. T. Whitehurst & John E. Brazier & Rosalie Viney & Brendan J. Mulhern - 1289-1295 Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?
by Luke B. Connelly & Stephen Birch - 1297-1308 Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies
by Aris Angelis & Huseyin Naci & Allan Hackshaw - 1309-1318 Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal
by Caroline Farmer & Ash Bullement & David Packman & Linda Long & Sophie Robinson & Elham Nikram & Anthony J. Hatswell & G. J. Melendez-Torres & Louise Crathorne - 1319-1331 Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach
by Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin - 1333-1343 Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles
by Ching-Yu Wang & Phuong N. Pham & Thuy N. Thai & Joshua D. Brown - 1345-1358 Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
by Lei Tian & Xiaomo Xiong & Qiang Guo & Yixi Chen & Luying Wang & Peng Dong & Aixia Ma - 1359-1372 Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups
by Shweta Mital & Hai V. Nguyen - 1373-1374 Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
by Richard Manning - 1375-1376 Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
by William V. Padula & Sonal Parasrampuria & Mariana P. Socal & Rena M. Conti & Gerard F. Anderson - 1377-1377 Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018
by David D. Kim & Madison C. Silver & Natalia Kunst & Joshua T. Cohen & Daniel A. Ollendorf & Peter J. Neumann
November 2020, Volume 38, Issue 11
- 1149-1151 On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?
by Kamal Desai & Eric Druyts & Kevin Yan & Chakrapani Balijepalli - 1153-1164 Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers
by Risha Gidwani & Louise B. Russell - 1165-1185 Integrative Review of Managed Entry Agreements: Chances and Limitations
by Carolina Zampirolli Dias & Brian Godman & Ludmila Peres Gargano & Pâmela Santos Azevedo & Marina Morgado Garcia & Maurílio Souza Cazarim & Laís Lessa Neiva Pantuzza & Nelio Gomes Ribeiro-Junior & André Luiz Pereira & Marcus Carvalho Borin & Isabella Figueiredo Zuppo & Roberto Iunes & Tomas Pippo & Renata Curi Hauegen & Carlos Vassalo & Tracey-Lea Laba & Steven Simoens & Sergio Márquez & Carolina Gomez & Luka Voncina & Gisbert W. Selke & Livio Garattini & Hye-Young Kwon & Jolanta Gulbinovic & Aneta Lipinska & Maciej Pomorski & Lindsay McClure & Jurij Fürst & Rosana Gambogi & Carla Hernandez Ortiz & Vânia Cristina Canuto Santos & Denizar Vianna Araújo & Vânia Eloisa Araujo & Francisco de Assis Acurcio & Juliana Alvares-Teodoro & Augusto Afonso Guerra-Junior - 1187-1200 Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer
by Erik F. Blom & Kevin ten Haaf & Harry J. Koning - 1201-1218 A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
by Wei Gao & Dominic Muston & Matthew Monberg & Kimmie McLaurin & Robert Hettle & Elizabeth Szamreta & Elyse Swallow & Su Zhang & Iden Kalemaj & James Signorovitch & R. Brett McQueen - 1219-1236 A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)
by Michael Urbich & Gary Globe & Krystallia Pantiri & Marieke Heisen & Craig Bennison & Heidi S. Wirtz & Gian Luca Di Tanna